Harrow, Inc. (NASDAQ:HROW) Shares Sold by Independent Advisor Alliance

Independent Advisor Alliance reduced its stake in shares of Harrow, Inc. (NASDAQ:HROW) by 43.7% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 5,789 shares of the company’s stock after selling 4,500 shares during the period. Independent Advisor Alliance’s holdings in Harrow were worth $260,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Vanguard Group Inc. lifted its position in Harrow by 1.2% during the first quarter. Vanguard Group Inc. now owns 1,829,805 shares of the company’s stock worth $24,208,000 after buying an additional 21,253 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in shares of Harrow by 6.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 16,672 shares of the company’s stock worth $221,000 after acquiring an additional 1,033 shares during the period. Bayesian Capital Management LP purchased a new position in shares of Harrow during the 1st quarter worth $185,000. Private Capital Management LLC boosted its position in shares of Harrow by 7.8% during the 1st quarter. Private Capital Management LLC now owns 3,012,393 shares of the company’s stock valued at $39,854,000 after acquiring an additional 217,896 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its holdings in shares of Harrow by 16.6% in the second quarter. Bank of New York Mellon Corp now owns 88,210 shares of the company’s stock valued at $1,843,000 after purchasing an additional 12,580 shares during the period. 72.76% of the stock is currently owned by institutional investors and hedge funds.

Harrow Trading Up 0.5 %

Shares of HROW stock opened at $42.47 on Friday. The company has a 50-day moving average of $47.68 and a two-hundred day moving average of $34.23. The firm has a market cap of $1.51 billion, a PE ratio of -45.18 and a beta of 0.76. Harrow, Inc. has a 1-year low of $8.72 and a 1-year high of $59.23. The company has a debt-to-equity ratio of 3.23, a current ratio of 1.55 and a quick ratio of 1.44.

Analysts Set New Price Targets

Several equities analysts have weighed in on HROW shares. Craig Hallum boosted their target price on shares of Harrow from $45.00 to $65.00 and gave the company a “buy” rating in a report on Friday, October 4th. Lake Street Capital lifted their price target on shares of Harrow from $45.00 to $55.00 and gave the company a “buy” rating in a research report on Friday, October 4th. Finally, B. Riley reiterated a “buy” rating and issued a $50.00 price objective on shares of Harrow in a research report on Thursday, August 29th.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.